Silence Therapeutics (SLN) FCF Margin: 2020-2025
Historic FCF Margin for Silence Therapeutics (SLN) over the last 5 years, with Sep 2025 value amounting to -6,857.23%.
- Silence Therapeutics' FCF Margin fell 514355.00% to -6,857.23% in Q3 2025 from the same period last year, while for Sep 2025 it was -281.06%, marking a year-over-year increase of 2349.00%. This contributed to the annual value of -156.85% for FY2024, which is 36.00% down from last year.
- According to the latest figures from Q3 2025, Silence Therapeutics' FCF Margin is -6,857.23%, which was up 29.67% from -9,749.55% recorded in Q2 2025.
- In the past 5 years, Silence Therapeutics' FCF Margin ranged from a high of 963.75% in Q2 2021 and a low of -9,749.55% during Q2 2025.
- Over the past 3 years, Silence Therapeutics' median FCF Margin value was -686.75% (recorded in 2024), while the average stood at -2,649.16%.
- In the last 5 years, Silence Therapeutics' FCF Margin soared by 75,238bps in 2024 and then plummeted by 906,280bps in 2025.
- Silence Therapeutics' FCF Margin (Quarterly) stood at -64.59% in 2021, then crashed by 21,680bps to -281.39% in 2022, then crashed by 57,983bps to -861.22% in 2023, then skyrocketed by 75,238bps to -108.84% in 2024, then crashed by 514,355bps to -6,857.23% in 2025.
- Its FCF Margin was -6,857.23% in Q3 2025, compared to -9,749.55% in Q2 2025 and -8,671.13% in Q1 2025.